The mechanism of action of treatment with tumour necrosis factor (TNF) blockers in rheumatoid arthritis (RA) is still not completely understood. The aim of this study was to test if adalimumab treatment could affect the infl ux of monocytes into the synovium. Methods A novel technique was used to analyse the migration of labelled autologous monocytes before and 14 days after initiation of adalimumab treatment using scintigraphy. CD14 monocytes were isolated from patients with RA, using a positive selection procedure with magnetic-activated cell sorting, and labelled with technetium-99m-hexamethylpropylene-amino-oxime. Scintigraphic scans were made 1, 2 and 3 h after re-infusion. Results As early as 14 days after the start of treatment with adalimumab a signifi cant decrease in disease activity score evaluated in 28 joints was shown. There was no signifi cant decrease in the infl ux of monocytes into the joint at this time. Conclusions This study indicates that adalimumab treatment does not reduce the infl ux of monocytes into the synovium early after initiation of treatment. As previous studies showed a rapid decrease in macrophage infi ltration after TNF-antibody therapy, which could not be explained by increased cell death, this points to an important role for enhanced effl ux of infl ammatory cells from the synovium.
INTRODUCTION
Disease control has been improved by the use of tumour necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA) and other immunemediated infl ammatory diseases. However, the mechanisms by which TNF antagonists exert their effect is still not completely understood. 1 Anti-TNF antibody treatment has been shown to result in marked reduction of synovial infl ammation in RA and psoriatic arthritis. 2 -4 This decrease in synovial cellularity could be observed as early as 24-48 h after initiation of treatment. 5 -7 This early reduction in synovial infl ammation after TNF blockade could not be explained by apoptosis induction at the site of infl ammation, 6 7 leaving either reduced cell infl ux or enhanced cell effl ux to explain this process. In one study infl iximab treatment signifi cantly decreased the infl ux of 111 In-labelled granulocyte migration into affected joints of RA patients, 4 and in another study adalimumab signifi cantly reduced infl ux of 99 Tc-labelled leucocytes, whereas no decrease in infl ux was seen in patients treated with placebo. 8 Monocytes and macrophages are key players in the pathogenesis of RA. 9 Furthermore, the decrease in macrophage numbers in the synovium is associated with clinical improvement after effective treatment. 10 Therefore, the effect of adalimumab treatment on monocyte migration towards the synovial compartment was examined. The authors recently developed a procedure using a combination of immunomagnetic cell selection with CD14-coated beads, labelling with technetium99m-hexamethylpropylene-amino-oxime and scintigraphy to visualise the migratory behaviour of autologous monocytes. 11 Applying this method, a continuous migration of monocytes into the infl amed synovial tissue of RA patients at a slow macrophage-replacement rate was shown. 12 The slow rate of monocyte infl ux into the synovial compartment suggests that the rapid effect of anti-TNF therapy on macrophage infi ltration cannot merely be explained by blockade of cell infl ux, as previously thought. Hence, this novel imaging technique was used to directly test if adalimumab treatment could affect the infl ux of monocytes into the synovium.
PATIENTS AND METHODS Patients
Eight patients with established RA according to the revised American College of Rheumatology criteria for the diagnosis of RA 13 were included. All patients had an indication for the use of anti-TNF therapy according to the guidelines of the Dutch Society for Rheumatology, which is active disease status (disease activity score evaluated in 28 joints (DAS28) ≥3.2) despite treatment with two conventional disease-modifying antirheumatic drugs. In this study all patients started with adalimumab (40 mg subcutaneously every other week) 24 h after the baseline scans. Three patients used maximally tolerable methotrexate at a stable dosage (10-25 mg/ week). The others received adalimumab monotherapy. The use of concomitant non-steroidal antiinfl ammatory drugs was permitted if stable for at least 1 month prior to baseline and was kept stable throughout the study. All patients provided written informed consent and approval was granted by the local medical ethics committee.
Isolation and labelling of monocytes
Isolation and labelling of monocytes was performed as described previously (see supplementary text).
Scintigraphy and signal calculations
Scintigraphy and signal calculations were done as described previously (see supplementary text). This procedure was done at day −14, baseline and day 14. 
DISCUSSION
The results of this mechanistic study indicate that CD14 monocyte infl ux into the synovium is not decreased 2 weeks after the start of adalimumab treatment. Earlier, TNF blockade was shown not to induce apoptosis in the synovium early after initiation of treatment, although the possibility cannot be excluded that more long-term treatment would lead to a more pro-apoptotic state, being a result of dampening of infl ammation rather than its cause. 1 This suggests that the rapid decrease in synovial macrophage numbers observed after anti-TNF treatment cannot be explained by an immediate effect on monocyte infl ux, as previously hypothesised. These data strengthen the recent observation that monocytes migrate towards the infl amed RA synovium at a slow macrophage-replacement rate, 12 which already suggested that blockade of monocyte migration would be insuffi cient to explain the rapid reduction of macrophage
Statistical analysis
Data were analysed using the Wilcoxon signed ranks test to determine signifi cant changes from baseline. Correlations were calculated using the Spearman's rank correlation coeffi cient. Values are expressed as median and IQR. The calculations were performed with SPSS 16.0 for Windows.
RESULTS

Patient characteristics
Half of the patients were IgM rheumatoid factor positive and all had erosive disease. Their median age was 53 (48.5-57) years and median disease duration was 162 (119-273) months. Individual patient characteristics are shown in table 1 .
Monocyte infl ux is stable and not markedly decreased early after initiation of adalimumab treatment
Scans were made 14 days prior to the start of adalimumab treatment, at baseline and 14 days after the start of adalimumab treatment (see supplementary fi gure 1 ). The number of labelled monocytes in the joint of interest per patient was comparable 1, 2 and 3 h after re-infusion. This was true for day −14, baseline and day 14 (see supplementary table). Monocyte infl ux per patient at 3 h postinfusion is shown in fi gure 1 . Of interest, there was no signifi cant change in monocyte infl ux 1, 2 and 3 h after re-infusion from day −14 to day 1, which was before the start of adalimumab treatment (p=0.33, p=0.67, p=0.21 respectively). The heterogeneity between patients is consistent with changes in synovial macrophages that were found in serial biopsies of patients treated with placebo. 14 Importantly, the infl ux of monocytes did not decrease after re-infusion of monocytes comparing day 14 to baseline, indicating that adalimumab treatment did not affect the infl ux of monocytes early after initiation of treatment ( fi gure 1 ).
Clinical benefi t of adalimumab treatment
The change in DAS28 from screening to day 84 is shown in fi gure 2 . The median DAS28 at baseline was 5.9 (4.8-7.2). The DAS28 did not change signifi cantly between screening and baseline (p=0.58). There was a statistically signifi cant decrease in median DAS28 from baseline to day 14 of 1.2 (0.72-1.8, p=0.01). At day 84 the median DAS28 had decreased to 2.8 (2.5-3.6) ( fi gure 2 ). Three patients were European League Against Rheumatism (EULAR) moderate responders to treatment and fi ve were EULAR good responders. There was no correlation between the decrease in DAS28, erythrocyte sedimentation rate or C reactive protein and the change in monocyte infl ux into the joints at 1, 2 or 3 h after re-infusion from baseline to 14 days (see supplementary fi gure 2 ). numbers found after anti-TNF treatment. Consistent with the hypothesis that TNF blockade does not interfere with high levels of monocyte infl ux into the synovial compartment, numbers of peripheral blood monocytes were not increased after initiation of infl iximab treatment. 7 This lack of reduction in monocyte infl ux is in contrast with previous work showing a reduction of labelled neutrophils into affected joints after treatment with TNFα blockers. 4 8 Of note, there is a clear difference in replacement rate for neutrophils compared to monocytes, as large numbers of neutrophils traffi c into the synovial fl uid. 15 In addition, the difference might be explained in part by the differential use of adhesion molecules between neutrophils and monocytes. Very late antigen-4/vascular cell adhesion molecule-1 (VLA-4/ VCAM-1) dependent rolling is seen mostly in monocytes, whereas adhesion of neutrophils is very much dependent on lymphocyte function-associated antigen 1/inter cellular adhesion molecule-1. 16 The reduced serum levels of sICAM-1 but not sVCAM-1 (refl ecting expression of adhesion molecules by endothelial cells) after administration of infl iximab could perhaps explain the sustained infl ux of monocytes while neutrophil infl ux is reduced. 17 In contrast to sVCAM-1 levels in peripheral blood, VCAM-1 expression in the synovial tissue is reduced after anti-TNF treatment. 3 7 VCAM-1 is especially highly expressed by fi broblastlike synoviocytes, and may play a crucial role in retention and survival of infi ltrating monocytes/macrophages. 18 Similarly, ICAM-1 expression is decreased in the tissue after TNF blockade. Thus, decreased expression of adhesion molecules 3 as well as chemokines 4 in the tissue may facilitate macrophage egress from the synovium, resulting in decreased macrophage numbers in the synovial tissue. In line with increased cell egress after anti-TNF treatment, it was found that anti-TNF therapy results in increased lymphatic vessel formation in the synovium. 19 Taken together, these data suggest that at this early time point the anti-infl ammatory effect of treatment with TNF blockers can only partly be explained by downregulation of vascular adhesion molecules on endothelial cells and subsequent reduction in migration of infl ammatory cells into the joint. Anti-TNF treatment may diminish RA disease activity by decreasing infl ammatory cell retention in the synovial tissue, for example, by reducing integrins expressed by fi broblast-like synoviocytes. Accordingly, treatments aimed at integrins such as anti-LFA-1 (efatizumab) and anti-VLA-4 were shown to be effective treatment in infl ammatory diseases, although serious infectious side effects were reported. 20 21 In conclusion, this study indicates that treatment with adalimumab does not reduce the infl ux of monocytes into the synovium 2 weeks after the start of treatment. In previous work early reduction in synovial infl ammation after TNF blockade could not be explained by apoptosis induction at the site of infl ammation. Based on these studies, it is hypothesised that effl ux of infl ammatory cells is a major contributor to the rapid reduction of cellularity after initiation of anti-TNF antibody therapy.
